GA Depot
(2026)Objective
To evaluate the efficacy and safety of GA Depot, a long-acting once-monthly intramuscular formulation of glatiramer acetate, compared with placebo in patients with relapsing multiple sclerosis.
Study Summary
• The trial assessed efficacy on relapse rate and MRI activity, along with safety, relative to placebo.
• Quantitative efficacy and safety results were not reported in the available source text.
Intervention
GA Depot — a long-acting, once-monthly intramuscular formulation of glatiramer acetate.
Inclusion Criteria
Patients with relapsing multiple sclerosis.
Study Design
Arms: GA Depot (long-acting once-monthly IM glatiramer acetate) vs Placebo (patient counts not reported in source)
Outcome
• Numeric outcome data (relapse rate, MRI lesion counts, p-values) were not provided in the source.
• Conclusions cannot be stated from the available abstract text.
Bottom Line
GA Depot, a once-monthly intramuscular glatiramer acetate, was tested against placebo in relapsing MS; specific efficacy and safety results were not reported in the available source text.
Major Points
- Phase 3 randomized, placebo-controlled trial of once-monthly intramuscular GA Depot in relapsing MS.
- Primary efficacy assessment focused on relapse rate and MRI activity, with safety evaluated relative to placebo.
- No quantitative efficacy, safety, or statistical results were available in the provided source text.
Study Design
- Study Type
- Phase 3 randomized controlled trial
- Randomization
- Yes
Primary Outcome
Definition: Efficacy on relapse rate and MRI activity (specific primary endpoint definition and results not reported in source).
| Control | Intervention | HR/OR | P-value |
|---|---|---|---|
| - |
Citation
Multiple Sclerosis Journal. February 2026. doi:10.1177/13524585251405101.